PlusTherapeuticsInc . (NASDAQ:PSTV) and SI-Bone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.
Earnings and Valuation
This table compares PlusTherapeuticsInc . and SI-Bone’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|PlusTherapeuticsInc .||$3.67 million||0.25||-$12.63 million||N/A||N/A|
|SI-Bone||$55.38 million||8.27||-$17.45 million||($0.71)||-25.82|
Institutional & Insider Ownership
88.9% of PlusTherapeuticsInc . shares are held by institutional investors. Comparatively, 51.0% of SI-Bone shares are held by institutional investors. 0.7% of PlusTherapeuticsInc . shares are held by company insiders. Comparatively, 38.8% of SI-Bone shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
PlusTherapeuticsInc . has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, SI-Bone has a beta of -0.59, indicating that its share price is 159% less volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for PlusTherapeuticsInc . and SI-Bone, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares PlusTherapeuticsInc . and SI-Bone’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
SI-Bone beats PlusTherapeuticsInc . on 6 of the 9 factors compared between the two stocks.
About PlusTherapeuticsInc .
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. It also engages in developing DoxoPLUS, an injectable generic PEGylated liposomal formulation of doxorubicin for the treatment of breast, ovarian, multiple myeloma, and Kaposi's sarcoma cancer. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for PlusTherapeuticsInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PlusTherapeuticsInc . and related companies with MarketBeat.com's FREE daily email newsletter.